ISSN: 2167-065X

Klinische Pharmakologie und Biopharmazeutik

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Revolutionizing Drug Discovery: The Role of Artificial Intelligence

Christo Molloy

The field of drug discovery has long been a challenging and time-consuming process, often requiring years of research and testing to develop new treatments for diseases. However, recent advancements in artificial intelligence (AI) have the potential to revolutionize the drug discovery process and significantly accelerate the development of new therapeutics. AI-based drug discovery methods involve using machine learning algorithms to analyze large datasets of biological and chemical information. This approach can quickly identify potential drug candidates and predict their efficacy, reducing the need for expensive and time-consuming experimental testing. One example of AI-based drug discovery is the use of deep learning algorithms to analyze the three-dimensional structure of proteins and predict how small molecules could bind to them. This approach has already led to the discovery of new drug candidates for diseases such as Alzheimer's and cancer.